CONRAD was established in 1986 under a cooperative agreement between Eastern Virginia Medical School (EVMS) and the U. S. Agency for International Development (USAID), but also receives funding through interagency agreements between USAID and the National Institute of Child Health and Human Development, the Centers for Disease Control and Prevention, and the National Institute of Allergy and Infectious Diseases. 

Current non-profit partners include Program for Appropriate Technology in Health (PATH), University of Utah, University of Pittsburgh (in particular, Microbicide Trials Network [MTN]), Brigham and Women’s Hospital, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Concept Foundation, Family Health International (FHI), Queen’s University Belfast, Oak Crest Institute of Science, Technology Innovation Agency (TIA) of South Africa, and the International Partnership for Microbicides (IPM). Current for-profit partners include Gilead, Medivir, and Controlled Therapeutics. Previous for-profit partners include Personal Products (J&J), Polydex, ReProtect, Biosyn, Schering AG (now Bayer Schering Pharma), Laboratorios Silesia (now part of Andromaco Group), Gedeon Richter, Aplicaciones Farmaceuticas, and Integra LifeSciences.

1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209   T: (703) 524-4744 | info@conrad.org